Efficacy Study of Zenapax in Combination With CellCept, Cyclosporine and Corticosteroids in Heart Transplant

This study has been completed.
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
First received: October 24, 2002
Last updated: December 15, 2005
Last verified: December 2005

The purpose of this study is to determine whether the combination of Zenapax, CellCept, Cyclosporine and Corticosteroids are effective in patients receiving heart transplants.

Condition Intervention Phase
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:


Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Undergoing heart transplant
  • Males or females who are 13 years or older
  • Women of childbearing potential must have a negative pregnancy test
  • Must be able to swallow tablets
  • Must be able to understand and comply with the study

Exclusion Criteria:

  • Previous transplants
  • Patients receiving multiple organs
  • HIV or Hepatitis
  • Patients with certain blood disorders
  • Patients who are taking certain experimental medicines
  • Women who are lactating or pregnant or who are unwilling to use two reliable forms of contraception
  • Severe diarrhea or other stomach problems
  • Cancer within the past 5 years (except for skin cancer that is treated)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00048165

  Show 36 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00048165     History of Changes
Other Study ID Numbers: NR15880
Study First Received: October 24, 2002
Last Updated: December 15, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014